NO981501L - Dimer-selektive RXR modulatorer og fremgangsmÕte for anvendelse derav - Google Patents

Dimer-selektive RXR modulatorer og fremgangsmÕte for anvendelse derav

Info

Publication number
NO981501L
NO981501L NO981501A NO981501A NO981501L NO 981501 L NO981501 L NO 981501L NO 981501 A NO981501 A NO 981501A NO 981501 A NO981501 A NO 981501A NO 981501 L NO981501 L NO 981501L
Authority
NO
Norway
Prior art keywords
dimer
image
selective rxr
rxr
rxr modulators
Prior art date
Application number
NO981501A
Other languages
English (en)
Other versions
NO981501D0 (no
NO313186B1 (no
Inventor
Lin Zhang
Alex M Nadzan
Richard A Heyman
Ranjan Mukherjee
Deepak S Lala
Luc J Farmer
Stacie Canan-Koch
Chan Kou Hwang
Marcus F Boehm
Beth Ann Badea
Laura J Dardashti
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27485410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO981501(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of NO981501D0 publication Critical patent/NO981501D0/no
Publication of NO981501L publication Critical patent/NO981501L/no
Publication of NO313186B1 publication Critical patent/NO313186B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33Polycyclic acids
    • C07C63/49Polycyclic acids containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66Polycyclic acids with unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/34Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
    • C07C65/36Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/08Aza-anthracenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19981501A 1995-10-06 1998-04-02 Dimer-selektive RXR modulatorer, farmasöytisk preparat omfattende samme og anvendelse derav for fremstilling avmedikament NO313186B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US489795P 1995-10-06 1995-10-06
US988496P 1996-01-10 1996-01-10
US1831896P 1996-05-24 1996-05-24
US2183996P 1996-07-10 1996-07-10
PCT/US1996/014876 WO1997012853A1 (en) 1995-10-06 1996-09-17 Dimer-selective rxr modulators and methods for their use

Publications (3)

Publication Number Publication Date
NO981501D0 NO981501D0 (no) 1998-04-02
NO981501L true NO981501L (no) 1998-06-02
NO313186B1 NO313186B1 (no) 2002-08-26

Family

ID=27485410

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981501A NO313186B1 (no) 1995-10-06 1998-04-02 Dimer-selektive RXR modulatorer, farmasöytisk preparat omfattende samme og anvendelse derav for fremstilling avmedikament

Country Status (14)

Country Link
US (2) US6545049B1 (no)
EP (2) EP1336600A3 (no)
JP (1) JP2002515025A (no)
KR (1) KR100625255B1 (no)
AT (1) ATE236115T1 (no)
AU (1) AU726450B2 (no)
BR (1) BR9610875A (no)
CA (1) CA2233888A1 (no)
DE (1) DE69627193T2 (no)
DK (1) DK0873295T3 (no)
ES (1) ES2190479T3 (no)
NO (1) NO313186B1 (no)
PT (1) PT873295E (no)
WO (1) WO1997012853A1 (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US7115728B1 (en) * 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
KR19990045756A (ko) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 Rxr 작용제를 이용하는 niddm 치료 방법
US6028052A (en) 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
US5998654A (en) * 1997-07-25 1999-12-07 Ligand Pharmaceuticals Incorporated Retinoic acid receptor antagonist compounds and methods
DE69835441T2 (de) * 1997-11-12 2007-08-02 F. Hoffmann-La Roche Ag Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
AU3700899A (en) * 1998-05-11 1999-11-29 Novo Nordisk A/S New compounds, their preparation and use
JP2002514616A (ja) * 1998-05-11 2002-05-21 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び使用
AU4676999A (en) 1998-06-12 1999-12-30 Ligand Pharmaceuticals, Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
FR2780512B1 (fr) * 1998-06-25 2003-10-17 Lipha Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique
US6147224A (en) * 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6403638B1 (en) 1998-10-01 2002-06-11 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6048873A (en) * 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
AU9556398A (en) * 1998-11-03 2000-05-22 Ligand Pharmaceuticals Incorporated Novel retinoids, methods for their production and use
ATE365158T1 (de) 1999-04-28 2007-07-15 Inst Med Molecular Design Inc Pyrimidincarbonsäurederivate
AU6941200A (en) 1999-08-27 2001-03-26 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
CZ2002711A3 (cs) 1999-08-27 2003-11-12 Ligand Pharmaceuticals Incorporated Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
WO2001015676A2 (en) * 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
WO2001019770A2 (en) * 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
EP1385549A2 (en) * 2001-03-12 2004-02-04 Novartis AG Combination of nateglinide or repaglinide with at least one further antidiabetic compound
MXPA03008229A (es) * 2001-03-14 2004-11-12 Lilly Co Eli Trienos fluorados y su uso como moduladores rxr.
US20040248913A1 (en) * 2001-07-20 2004-12-09 Grese Timothy Alan (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
US6759547B1 (en) 2003-01-14 2004-07-06 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
US7019034B2 (en) 2003-01-28 2006-03-28 Allergan, Inc. Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en) 2003-02-04 2004-07-06 Allergan, Inc. 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en) 2003-04-03 2005-04-26 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
CA2598216C (en) 2005-06-17 2014-04-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
DK2262364T3 (en) * 2008-03-07 2016-03-21 Vtv Therapeutics Llc Oxadiazoanthracenforbindelser for the treatment of diabetes
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
US9174917B2 (en) 2010-02-19 2015-11-03 Arizona Board Of Regents On Behalf Of Arizona State University Bexarotene analogs
AU2012308582B2 (en) 2011-09-15 2016-11-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
JP5877466B2 (ja) * 2012-02-29 2016-03-08 国立大学法人 岡山大学 テルペノイド由来レチノイド化合物
CN107074800B (zh) * 2014-01-14 2019-11-12 康内克斯生命科学私人有限公司 经取代的双环杂芳基化合物作为rxr促效剂
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
JP7178781B2 (ja) * 2014-10-10 2022-11-28 ハイ フォース リサーチ リミテッド 蛍光合成レチノイド
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2018155260A1 (ja) * 2017-02-23 2018-08-30 株式会社Ihi Ohラジカル検出プローブ、ohラジカル測定装置、および、ohラジカル測定方法
WO2019169270A1 (en) * 2018-03-01 2019-09-06 Dawn Scientific Pharmaceuticals, Llc Bexarotene derivatives and their use in treating cancer
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845089A (en) * 1972-07-27 1974-10-29 Zoecon Corp Phenylheptadienoates
US4215215A (en) * 1975-08-01 1980-07-29 Hoffmann-La Roche Inc. 9-Phenyl-nonate traene compounds
US4105681A (en) * 1975-08-01 1978-08-08 Hoffmann-La Roche Inc. 9-phenyl 5,6-dimethyl-nona-2,4,6,8-tetraeonic acid compounds
LU77254A1 (no) 1977-05-04 1979-01-18
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
DE3202100A1 (de) * 1982-01-23 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
CH651034A5 (de) 1982-05-12 1985-08-30 Hoffmann La Roche Chroman-, thiochroman- oder 1,2,3,4-tetrahydrochinolinderivate und ihre verwendung als arzneimittel-wirkstoffe.
US4534979A (en) 1982-06-28 1985-08-13 Usv Pharmaceutical Corp. Polyene compounds useful in the treatment of psoriasis and allergic responses
US4539134A (en) * 1982-12-02 1985-09-03 Halliburton Company Methods and cleaning compositions for removing organic materials from metallic surfaces
US4539154A (en) 1983-06-15 1985-09-03 Hoffmann-La Roche Inc. Polyene compounds
US4648996A (en) * 1984-07-27 1987-03-10 Hoffmann-La Roche Inc. Phenyl substituted-2,4,6,8-nonatetraenoic acid
US4783549A (en) * 1984-09-05 1988-11-08 L'oreal Benzonorbornene derivatives, processes for their preparation and medicinal and cosmetic compositions containing them
DE3434944A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen L-substituierte tetralinderivate, ihre herstellung und verwendung
FR2580277B1 (fr) 1985-04-15 1988-06-10 Oreal Nouveaux derives naphtaleniques a action retinoique, le ur procede de preparation et compositions medicamenteuse et cosmetique les contenant
LU86022A1 (fr) 1985-07-25 1987-02-04 Cird Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique
JPS62215581A (ja) 1986-03-18 1987-09-22 Koichi Shiyudo フラボンカルボン酸誘導体
FR2599031B1 (fr) * 1986-05-23 1988-07-22 Oreal Nouveaux composes naphtyl aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
FR2601670B1 (fr) 1986-07-17 1988-10-07 Cird Nouveaux derives bicycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
FR2605626B1 (fr) 1986-10-27 1989-06-02 Oreal Nouveaux derives aromatiques bicycliques, leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire
FR2614618B1 (fr) 1987-04-30 1989-07-07 Cird Derives heterocycliques polycycliques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire
US4977276A (en) * 1987-05-11 1990-12-11 The Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges Acting For And On Behalf Of Oklahoma State Univ. Heteroarotinoids as anticancer agents
LU87040A1 (fr) 1987-11-04 1989-06-14 Oreal Esters aromatiques polycycliques d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
DE4036779A1 (de) 1990-11-17 1992-05-21 Basf Ag Verwendung von arylpolyencarbonsaeuren und ihren derivaten als lichtschutzmittel in kosmetischen zubereitungen
ATE208194T1 (de) 1991-08-23 2001-11-15 Salk Inst For Biological Studi Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen
US5668175A (en) 1991-08-23 1997-09-16 The Salk Institute For Biological Studies Use of selective ligands for treatment of disease states responsive to steroid or steroid-like retinoids
AU675430B2 (en) * 1992-04-22 1997-02-06 Ligand Pharmaceuticals Incorporated Compounds having selectivity for retinoid X receptors
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
US5552271A (en) 1992-06-16 1996-09-03 La Jolla Cancer Research Foundation RXR homodimer formation
US5391569A (en) 1992-09-29 1995-02-21 Adir Et Compagnie New chromene compounds having a triene side chain
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
CA2149882A1 (en) 1992-11-25 1994-06-09 Magnus Pfahl Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
PT678086E (pt) * 1993-01-11 2000-05-31 Ligand Pharm Inc Compostos com selectividade para receptores de retinoides x
WO1995004036A1 (en) * 1993-01-11 1995-02-09 Ligand Pharmaceuticals Inc. Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
WO1994015901A1 (en) * 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
WO1995015901A1 (en) * 1993-12-08 1995-06-15 Beloit Technologies, Inc. Method and apparatus for effecting a set change in a paper winder
FR2719042B1 (fr) * 1994-04-25 1996-05-15 Rhone Poulenc Chimie Procédé de préparation d'un acide alpha-(hydroxyphénoxy)- alcanecarboxylique optiquement actif.
FR2719041B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
FR2723315B1 (fr) 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
ATE181052T1 (de) 1994-08-10 1999-06-15 Hoffmann La Roche Retinoesäure x-rezeptor liganden
US5977125A (en) 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5968908A (en) 1994-12-19 1999-10-19 American Cyanamid Company Restricted 9-cis retinoids
IL116259A (en) 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
FR2729664A1 (fr) * 1995-01-20 1996-07-26 Cird Galderma Composes bicycliques-aromatiques a forte activite biologique compositions pharmaceutiques et cosmetiques les contenant et utilisations
CZ212097A3 (en) 1995-01-20 1997-11-12 Novo Nordisk As Use of 3,4-diphenylchromans for preparing a medicament intended for treating or prophylaxis of cerebral degenerative diseases
JP2002514616A (ja) 1998-05-11 2002-05-21 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び使用

Also Published As

Publication number Publication date
CA2233888A1 (en) 1997-04-10
ATE236115T1 (de) 2003-04-15
AU7362496A (en) 1997-04-28
BR9610875A (pt) 1999-07-13
EP0873295A1 (en) 1998-10-28
NO981501D0 (no) 1998-04-02
AU726450B2 (en) 2000-11-09
KR100625255B1 (ko) 2008-01-30
PT873295E (pt) 2003-08-29
WO1997012853A1 (en) 1997-04-10
NO313186B1 (no) 2002-08-26
US6545049B1 (en) 2003-04-08
EP0873295B1 (en) 2003-04-02
DE69627193D1 (de) 2003-05-08
DE69627193T2 (de) 2004-01-29
EP1336600A3 (en) 2004-07-07
KR19990064010A (ko) 1999-07-26
JP2002515025A (ja) 2002-05-21
US20040019072A1 (en) 2004-01-29
DK0873295T3 (da) 2003-07-14
ES2190479T3 (es) 2003-08-01
EP1336600A2 (en) 2003-08-20

Similar Documents

Publication Publication Date Title
NO981501L (no) Dimer-selektive RXR modulatorer og fremgangsmÕte for anvendelse derav
DK0800519T3 (da) Steroidreceptormodulatorforbindelser og fremgangsmåder
BR9710988A (pt) Método e compostos moduladores receptores de androgênio
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
PT1153626E (pt) Aparelho de administracao de medicamentos
DE69727176D1 (de) Apparat zur stereotaktischen Laserchirurgie
MA24357A1 (fr) Methode et dispositif pour dactylographie rapide.
FI960853A (fi) Laite ja menetelmä olefiinien polymeroimiseksi
DE69412195D1 (de) Gerät zur Abbildung von Hornhaut-Zellen
IT1280812B1 (it) Apparecchio per magnetoterapia.
IT229493Y1 (it) Apparecchio didattico e di esercitazione di uso odontoiatrico.
FR2717926B1 (fr) Dispositif et procédé de combinaison d'images.
MX9305998A (es) 6-heterociclic-4-amino-1, 3, 4, 5,-tetrahidrobenz[cd] indoles yprocedimiento para su preparacion.
NO307364B1 (no) Anvendelse av melatoninderivater
DK0693912T3 (da) Apparat til medicinsk behandling
FR2735031B1 (fr) Appareil d'anesthesie loco-regionale.
DK105296A (da) Diffusionstågeapparat
NO931014L (no) Farmasoeytisk preparat
IT1287793B1 (it) Procedimento e dispositivo per la realizzazione di segnaletiche stradali orizzontali.
KR950010433U (ko) 모니터용 보안기의 착탈장치
KR960029855U (ko) 모니터의 포커싱장치
FR2685545B1 (fr) Tete d'emission pour appareil de radiographie-eclair.
FI973228A (fi) Terapeuttisten yhdisteiden testausmenetelmä
ITMI920727A0 (it) Dispositivo per la riproduzione di immagini
ITPR940011A0 (it) Procedimento e dispositivo automatico di controllo dell'immagine di oggetti.